Highlights Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:11 2024-05-08 am EDT			5-day change	1st Jan Change
37.75 ^HKD	+6.04%		+4.28%	-23.12%

Apr. 30	Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA	MT
Apr. 29	Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA	Apr. 29	MT
Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points	Apr. 28	MT
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis	Apr. 28	CI
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	Apr. 11	MT
KeyMed Biosciences’ Attributable Loss Widens in 2023	Mar. 27	MT
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Keymed Biosciences Buys Back Shares	Jan. 22	MT
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps	Dec. 26	CI
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection	Dec. 06	CI
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901	Nov. 07	CI
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023	23-10-11	CI
Keymed Biosciences’ Profit Surges in H1	23-08-25	MT
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Keymed Biosciences to Acquire 18.7% of Kangnuo Xing for 150.6 Million Yuan	23-06-27	MT
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313	23-06-11	CI
Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults	23-05-29	CI
Keymed Biosciences Inc. Announces Phase III Confirmatory Clinical Study of Its Self-Developed Class 1 Innovative Drug CM310 Recombinant Humanized Monoclonal Antibody Injection	23-03-28	CI
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05	23-02-23	CI
Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901	23-02-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Highlights

Filters